Cite
HARVARD Citation
Andrews, K. et al. (n.d.). NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models. European journal of cancer. pp. S76-S77. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Andrews, K. et al. (n.d.). NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models. European journal of cancer. pp. S76-S77. [Online].